Exact Mass: 452.2725

Exact Mass Matches: 452.2725

Found 147 metabolites which its exact mass value is equals to given mass value 452.2725, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Repaglinide

2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid

C27H36N2O4 (452.2675)

Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naive to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90\\% of a single orally administered dose is eliminated in feces and 8\\% in urine. C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents

7-O-Dmethylcephaeline

7-O-Demethylcephaeline

C27H36N2O4 (452.2675)

Tribendimidine

N-(4-{[(4-{[(4-{[1-(dimethylamino)ethylidene]amino}phenyl)imino]methyl}phenyl)methylidene]amino}phenyl)-N,N-dimethylethanimidamide

C28H32N6 (452.2688)

Tribendimidine is an orally active, broad-spectrum anthelmintic agent, with particularly high activity against A. lumbricoides and N. americanus. Tribendimidine is also an L-type nicotinic acetylcholine receptor (nAChR) agonist[1][2][3].

DG(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0)

(2S)-1-(Acetyloxy)-3-hydroxypropan-2-yl (5R,6Z,8E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid

C25H40O7 (452.2774)

DG(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0/0:0)

(2S)-2-(acetyloxy)-3-hydroxypropyl (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate

C25H40O7 (452.2774)

DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(2:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

(2R)-3-(Acetyloxy)-2-hydroxypropyl (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid

C25H40O7 (452.2774)

DG(2:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/2:0)

(2S)-3-(Acetyloxy)-2-hydroxypropyl (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid

C25H40O7 (452.2774)

DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0)

(2S)-1-(Acetyloxy)-3-hydroxypropan-2-yl (5S,6E,8Z,11Z,15R)-5,15-dihydroxyicosa-6,8,11,13-tetraenoic acid

C25H40O7 (452.2774)

DG(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0/0:0)

(2S)-2-(acetyloxy)-3-hydroxypropyl (5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoate

C25H40O7 (452.2774)

DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(2:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

(2R)-3-(acetyloxy)-2-hydroxypropyl (5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoate

C25H40O7 (452.2774)

DG(2:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/2:0)

(2S)-3-(acetyloxy)-2-hydroxypropyl (5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoate

C25H40O7 (452.2774)

DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0)

(2S)-1-(Acetyloxy)-3-hydroxypropan-2-yl (5R,6R,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoic acid

C25H40O7 (452.2774)

DG(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0/0:0)

(2S)-2-(Acetyloxy)-3-hydroxypropyl (5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoic acid

C25H40O7 (452.2774)

DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(2:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

(2R)-3-(Acetyloxy)-2-hydroxypropyl (5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoic acid

C25H40O7 (452.2774)

DG(2:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/2:0)

(2S)-3-(Acetyloxy)-2-hydroxypropyl (5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoic acid

C25H40O7 (452.2774)

DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

10-O-Demethylcephaeline

(-)-10-Demethylcephaeline

C27H36N2O4 (452.2675)

7-O-Demethylisocephaeline

(-)-7-O-Demethylisocephaeline

C27H36N2O4 (452.2675)

A pyridoisoquinoline consisting of (1beta)-emetan substituted by hydroxy groups at positions 6 and 7 and methoxy groups at positions 10 and 11. It is isolated from Psychotria klugii and exhibits antileishmanial activity.

9-O-Demethylcephaeline

C27H36N2O4 (452.2675)

(E)-5-hydroxy-N-[3-[5-[3-[[(E)-5-hydroxy-3-methylpent-2-enoyl]amino]propyl]-3,6-dioxopiperazin-2-yl]propyl]-3-methylpent-2-enamide

C22H36N4O6 (452.2635)

Laserpitinol

C25H40O7 (452.2774)

methyl-13S-hydroxy-14R,15-diacetoxy-1(10)-ent-halimen-18-oate

C25H40O7 (452.2774)

grindelic acid 15-O-arabinoside

C25H40O7 (452.2774)

14,15-Di-Ac,17-Me ester-13,14,15-Trihydroxy-7-labden-17-oic acid

C25H40O7 (452.2774)

Ecdysteron

C25H40O7 (452.2774)

C25H40O7

C25H40O7 (452.2774)

dothideomycetone B

C25H40O7 (452.2774)

5,6-acetonylgrayanotoxin-I

C25H40O7 (452.2774)

18-methylmalonyl-7alpha-hydroxy-methyltrineracetal

C25H40O7 (452.2774)

L-MeIle-L-Acm-L-Glu

C22H36N4O6 (452.2635)

6alpha,8alpha,23,14,15-erythro-pentahydroxy-labd-13(21),17-dien-16,19-olide|6alpha,8alpha,23,14,15-threo-pentahydroxy-labd-13(21),17-dien-16,19-olide

C25H40O7 (452.2774)

6beta,7beta,11beta,14beta,15beta-pentahydroxy-20-isoamoxy-7alpha,20-epoxy-ent-kaur-16-ene|hebeirubescensin F

C25H40O7 (452.2774)

Tomentin

C25H40O7 (452.2774)

Repaglinide

C27H36N2O4 (452.2675)

C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents CONFIDENCE standard compound; INTERNAL_ID 2189 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3349

Ala His Ile Ile

(2S,3S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylpentanamido]-3-methylpentanoic acid